Biological intelligence for brain health and neurodegenerative disease
Brainalyze Neuro
Brainalyze Neuro is the first clinical product family built on Brainalyze’s biochemical-fingerprinting platform. It is designed to support a growing product pipeline across neurological triage, classification, stratification, monitoring, and treatment response.
Beyond single diseases and predefined biomarkers, toward a broader understanding of neurological state and change.
The Biochemical Fingerprint Database
Every Fingerprint Matters
Every patient generates:
-
A biochemical fingerprint
-
Clinical metadata
-
Disease intelligence
Compounding Data Flywheel
One platform. A growing neurological product family
Patients can present with cognitive, behavioral, or motor changes arising from multiple neurological conditions, comorbidities, and disease stages. Brainalyze Neuro is being developed to support different decisions across the care and therapeutic-development pathway.
-
Triage
Route patients toward appropriate evaluation and care pathways. -
Classification
Differentiate biological patterns associated with neurological conditions. -
Stratification
Support patient and cohort selection for care and clinical trials. -
Monitoring
Measure disease-associated change over time. -
Treatment response
Support therapeutic development and response assessment.
NeuroTriage is the first planned product within Brainalyze Neuro, providing a focused commercial entry into the broader neurological-intelligence opportunity.​
Rapid test with accuracy benchmarked against current gold standard
Brainalyze refined their solution through work with the NHS. With access to a cohort of 141 patients already diagnosed with Alzheimer’s, some of whom had waited 2 years for a diagnosis, Brainalyze were able to recreate these detections faster and with a high degree of accuracy.
Brainalyze’s diagnostic aid is different to the antibody-based blood tests already in use in some markets. These tests can only detect Alzheimer’s disease but also require specialised labs and kits whereas Brainalyze’s simple test is holistic, works across dementia types, and is rapid. To secure the future of their solution and further progress, a patent application protecting the method and device technology has already been awarded in the US and is pending elsewhere.
Successful and progressing patent applications
Winning grant funding to continue research and development
The team have secured Alzheimer’s Research UK Fellowship funding to continue their research, as well as a £1.2 million UKRI Cross-Council grant as part of the interdisciplinary HOpE project for further technology validation.
Demonstrating early detection and differential diagnosis
The team have analysed 100s of patient blood samples, with further validation on-going. The results clearly establish early detection capabilities of Brainalyze's blood test.
Progress
Published and unpublished research studies validate the platform and demonstrate the potential opportunity
Publications
Devitt, G., Michopoulou, S., Kadalayil, L., Hanrahan, N., Prosser, A., Ghosh, B., Mudher, A., Kipps, C. and Mahajan, S., 2025.
Classification of Alzheimer’s disease in a mixed clinical cohort using biofluid Raman spectroscopy. medRxiv, pp.2025-02.
Devitt, G., Hanrahan, N., Moreno, M.R., Mudher, A. and Mahajan, S., 2024.
A Novel Spectral Barcoding and Classification Approach for Complex Biological Samples using Multi-excitation Raman Spectroscopy (MX-Raman).
Huefner, A., Kuan, W.L., Mason, S.L., Mahajan, S. and Barker, R.A., 2019.
Serum Raman spectroscopy as a diagnostic tool in patients with Huntington's disease.
United States Patent Application 20250052683
MULTI-EXCITATION RAMAN SPECTROSCOPY METHOD AND APPARATUS
Devitt, G., Michopoulou, S., Kadalayil, L., Hanrahan, N., Prosser, A., Ghosh, B., Mudher, A., Kipps, C. and Mahajan, S., 2025.
Classification of Alzheimer’s disease in a mixed clinical cohort using biofluid Raman spectroscopy. medRxiv, pp.2025-02.
Devitt, G., Hanrahan, N., Moreno, M.R., Mudher, A. and Mahajan, S., 2024.
A Novel Spectral Barcoding and Classification Approach for Complex Biological Samples using Multi-excitation Raman Spectroscopy (MX-Raman).
Huefner, A., Kuan, W.L., Mason, S.L., Mahajan, S. and Barker, R.A., 2019.
Serum Raman spectroscopy as a diagnostic tool in patients with Huntington's disease.
United States Patent Application 20250052683
MULTI-EXCITATION RAMAN SPECTROSCOPY METHOD AND APPARATUS